Redmile Group LLC trimmed its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 10.1% in the first quarter, HoldingsChannel.com reports. The fund owned 2,001,467 shares of the company’s stock after selling 226,040 shares during the period. Redmile Group LLC owned 0.08% of Oxford Immunotec Global worth $34,485,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. FIL Ltd acquired a new stake in Oxford Immunotec Global in the 1st quarter valued at about $5,586,000. Martingale Asset Management L P acquired a new stake in Oxford Immunotec Global in the 4th quarter valued at about $1,499,000. Bellevue Group AG raised its position in Oxford Immunotec Global by 38.2% in the 4th quarter. Bellevue Group AG now owns 306,606 shares of the company’s stock valued at $3,918,000 after purchasing an additional 84,769 shares in the last quarter. EAM Global Investors LLC acquired a new stake in Oxford Immunotec Global in the 1st quarter valued at about $1,330,000. Finally, Marshall Wace LLP acquired a new stake in Oxford Immunotec Global in the 1st quarter valued at about $1,185,000. Institutional investors own 91.57% of the company’s stock.

OXFD stock opened at $14.07 on Monday. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $374.59 million, a price-to-earnings ratio of 27.59 and a beta of 0.42. Oxford Immunotec Global PLC has a 1 year low of $11.66 and a 1 year high of $19.19.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14. The company had revenue of $14.79 million for the quarter, compared to analyst estimates of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. Oxford Immunotec Global’s revenue for the quarter was up 26.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.40) EPS. Equities analysts forecast that Oxford Immunotec Global PLC will post -0.28 EPS for the current fiscal year.

In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total transaction of $48,150.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at approximately $48,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 10,600 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $16.68, for a total value of $176,808.00. Following the sale, the chief executive officer now directly owns 445,138 shares in the company, valued at approximately $7,424,901.84. The disclosure for this sale can be found here. 6.61% of the stock is currently owned by company insiders.

A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $18.00.

ILLEGAL ACTIVITY NOTICE: “Oxford Immunotec Global PLC (NASDAQ:OXFD) Shares Sold by Redmile Group LLC” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/oxford-immunotec-global-plc-nasdaqoxfd-shares-sold-by-redmile-group-llc/3044118.html.

Oxford Immunotec Global Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Featured Story: Liquidity

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.